<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_IISc-Bangalore_Description skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:IISc-Bangalore/Description</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P><NAV class="navbar navbar-expand-lg navbar-light fixed-top" style="background-color: #ffffff; top:16px; font-family: bodyfont;"><UL class="navbar-nav collapse navbar-collapse justify-content-end" id="navbarSupportedContent" style="padding-right: 40px;"><LI class="nav-item"><A class="nav-link" href="https://2018.igem.org/Team:IISc-Bangalore">Home</A></LI><LI class="nav-item dropdown"><A class="nav-link dropdown-toggle" href="#" id="navbarDropdown" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                    Project
                </A><DIV class="dropdown-menu" aria-labelledby="navbarDropdown"><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/Description">Overview</A><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/PACMAN">PACMAN</A><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/PAIR">PAIR</A><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/APES">APES</A><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/Design">Design</A><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/Experiments">Experiments</A><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/Parts">Parts</A><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/Model">Model</A></DIV></LI><LI class="nav-item dropdown"><A class="nav-link dropdown-toggle" href="#" id="navbarDropdown" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                        Lab
                    </A><DIV class="dropdown-menu" aria-labelledby="navbarDropdown"><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/Notebook">Notebook</A><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/Protocols">Protocols</A><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/Assembly">Assembly</A><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/Results">Results</A><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/InterLab">InterLab</A><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/Improve">Improve</A></DIV></LI><LI class="nav-item dropdown"><A class="nav-link dropdown-toggle" href="#" id="navbarDropdown" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">Software</A><DIV class="dropdown-menu" aria-labelledby="navbarDropdown"><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/Software">PhageModifier</A></DIV></LI><LI class="nav-item dropdown"><A class="nav-link dropdown-toggle" href="#" id="navbarDropdown" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                            Community
                        </A><DIV class="dropdown-menu" aria-labelledby="navbarDropdown"><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/Collaborations">Collaborations</A><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/Human_Practices">Human Practices</A><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/Integrated_HP">Integrated HP</A><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/Public_Engagement">Public Engagement</A><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/Safety">Safety</A><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/Survey">Survey</A></DIV></LI><LI class="nav-item dropdown"><A class="nav-link dropdown-toggle" href="#" id="navbarDropdown" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                    Team
                </A><DIV class="dropdown-menu" aria-labelledby="navbarDropdown"><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/Team">Members</A><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/Philosophy">Philosophy</A><A class="dropdown-item" href="https://2018.igem.org/Team:IISc-Bangalore/Attributions">Attributions</A></DIV></LI></UL></NAV></P><DIV class="jumbotron" style="background-color: white; background-image: url(https://static.igem.org/mediawiki/2018/7/72/T--IISc-Bangalore--pageDescription.png); height: 300px; background-size: 100%; background-repeat: no-repeat;"><H1 style="text-align: center; top: 40px; position: relative; color:white; font-family: headfont;"><B>Overview</B></H1></DIV><DIV class="container" style="padding: 30px;"><H2><B>The tragedy of the antibiotic</B></H2><P>In 1929, a largely unnoticed paper appeared in the British Journal of Experimental Pathology by a less known army doctor named Alexander Fleming highlighting the use of a fungally isolated compound as an antibacterial. This compound was Penicillin, a molecule that single-handedly revolutionized the way infections were treated because of its extreme stability and ease of isolation. Antibiotics soon became a buzzword with an increasingly large number of such compounds being discovered by multiple groups over the world. </P><P>At the same time, in another part of the world, a long known cure for bacterial infections started losing its charm. This cure used <B>phages</B> - which are viruses that infect bacteria - to eliminate bacterial pathogens. However, the ease with which antibiotics could be modified (chemically) and characterized for negative effects completely knocked phage therapy off the treatment map.</P><CENTER><BUTTON data-toggle="collapse" data-target="#timeline" class="btn btn-default">Phage history timeline</BUTTON></CENTER><P>While these events unrolled, a new and critical problem started coming into the picture, that of <B>antibiotic resistance</B>. Bacteria are constantly evolving, adapting creatures. Over generations, with the accumulation of mutations over marginally fitter phenotypes, they are capable of evolving into an organism that is significantly resistant to the antibiotic. </P><P>In January 2018, right when we were on a lookout for idea, a very interesting article<SUP>[1]</SUP> appeared on the website of <I>The Bureau of Investigative Journalism</I>. This article mentioned <B>colistin - a last resort antibiotic</B> - which was turning out to be a major cause of worry for people both in India and the rest of the world. After a <A href="https://2018.igem.org/Team:IISc-Bangalore/Integrated_HP">lot more research</A> into this direction, we realised the true magnitude of the problem.</P><P>Colistin belongs to the polymyxin class of antibiotics, a class which is given the <B>highest priority in the WHO list of critically important antimicrobials</B><SUP>[2]</SUP>. In spite of this, it is <B>being used by poultry farmers across the country (and abroad) as a growth promoter for increasing the yield of meat.</B></P><CENTER><FIGURE><FIGCAPTION style="font-size:14px;"><I>WHO list of critically important antimicrobials</I></FIGCAPTION></FIGURE></CENTER><P>After a quick search we found at least three manufacturers in India selling colistin or colistin containing additives for chicken feed. One manufacturer even claimed that colistin &quot;does not lead to resistance by bacterial selection&quot;. The stark difference in awareness and concerns for antibiotic resistance between these two groups was surprising.</P><H2><B>A possible solution?</B></H2><P>Phages come out as a seemingly obvious alternative to antibiotics when one tries to look at the bigger picture. The reasoning being the following:</P><UL style="font-size:16px; font-family:bodyfont;"><LI>Being biological agents, they can <B>co-evolve</B> in a continuous arms race against bacteria.</LI><LI>They increase in number specifically at the site of infection - a process referred to as <B>autodosing</B> thus preventing any side affects from non-specific targeting.</LI><LI>The process of <B>phage discovery is much faster and much more straightforward</B> than the process of antibiotic discovery.</LI></UL><P>On close analysis, however, it is revealed that this methodology itself is not free of a wide variety of problems. Some of the most prominent ones being:</P><UL style="font-size:16px; font-family:bodyfont;"><LI>While they do mutate and co-evolve, the rate of <B>phage evolution is not fast enough</B> to be within the lifetime of a single patient. As such they also suffer from the same integral problem as antibiotics.</LI><LI>Phages, being viruses, are <B>not perceived in a very positive manner</B> among the general populus.</LI><LI>The <B>rules and regulations</B> for administration of phages are neither clear nor very reasonable considering they are a completely new modality for treatment.</LI><LI>Both phages and antibiotics <B>lead to bacterial endotoxin release</B>, an especially severe problem for patients with possibilities of multi-organ failure</LI></UL><H1 style="font-size:40px;"><B>PhageShift as a project started with the following goals in mind</B></H1><DIV class="row"><DIV class="col-sm-4" style="text-align:center; height:400px; border-right: 2px solid #efefef;"><H2 style="font-size:40px; margin-top:100px;"><B>Goal 1</B></H2></DIV><DIV class="col-sm-8" style="text-align:center; height:450px;"><H3 style="text-decoration: none;"><B>To engineer a phage that is either less prone to become obsolete due to bacterial resistance or improves the performance of conventional antibiotics</B></H3><BUTTON type="button" class="btn btn-outline-dark"><A href="https://2018.igem.org/Team:IISc-Bangalore/PACMAN" target="_blank"><H4 style="font-size:35px;"><B>PACMAN</B></H4></A></BUTTON><BUTTON type="button" class="btn btn-outline-dark"><A href="https://2018.igem.org/Team:IISc-Bangalore/Software" target="_blank"><H4 style="font-size:35px;"><B>PhageModifier</B></H4></A></BUTTON><H5><B>Phage Antibiotic Complementarity Mediated Antimicrobial Network and a software to implement it</B></H5></DIV></DIV><DIV class="row"><DIV class="col-sm-8" style="text-align:center; height:400px; border-right: 2px solid #efefef;"><H3 style="text-decoration: none;"><B>To make the public more aware about phages and how they might be a possible solution to the antibiotic resistance crisis</B></H3><BUTTON type="button" class="btn btn-outline-dark"><A href="https://2018.igem.org/Team:IISc-Bangalore/Public_Engagement" target="_blank"><H4 style="font-size:35px;"><B>Public Engagement</B></H4></A></BUTTON></DIV><DIV class="col-sm-4" style="text-align:center; height:400px;"><H2 style="font-size:40px; margin-top:100px;"><B>Goal 2</B></H2></DIV></DIV><DIV class="row"><DIV class="col-sm-4" style="text-align:center; height:400px; border-right: 2px solid #efefef;"><H2 style="font-size:40px; margin-top:100px;"><B>Goal 3</B></H2></DIV><DIV class="col-sm-8" style="text-align:center; height:400px;"><H3 style="text-decoration: none;"><B>To survey the current policy on phage therapeutics and come up with the necessary changes required to make phage therapy legally acceptable</B></H3><BUTTON type="button" class="btn btn-outline-dark"><A href="https://2018.igem.org/Team:IISc-Bangalore/Integrated_HP#lawshp" target="_blank"><H4 style="font-size:35px;"><B> Phage Regulations </B></H4></A></BUTTON></DIV></DIV><DIV class="row"><DIV class="col-sm-8" style="text-align:center; height:400px; border-right: 2px solid #efefef;"><H4 style="text-decoration: none;"><B>To develop a system for rapid development of phage cocktails against resistant bacteria</B></H4><BUTTON type="button" class="btn btn-outline-dark"><A href="https://2018.igem.org/Team:IISc-Bangalore/APES" target="_blank"><H4 style="font-size:35px;"><B>APES</B></H4></A></BUTTON><H5><B>Accelerated Phage Evolution System</B></H5></DIV><DIV class="col-sm-4" style="text-align:center; height:400px;"><H2 style="font-size:40px; margin-top:100px;"><B>Goal 4</B></H2></DIV></DIV><H2><B>While working on these goals, we realised two more integral problems with phage therapy</B></H2><DIV class="row"><DIV class="col-sm-6" style="text-align: center;"><H2><B>through our <A href="https://2018.igem.org/Team:IISc-Bangalore/Integrated_HP#doc" target="_blank">interactions with Medical professionals</A></B></H2></DIV><DIV class="col-sm-6" style="text-align: center;"><H2><B>through our <A href="https://2018.igem.org/Team:IISc-Bangalore/Integrated_HP#gan" target="_blank">interaction with GangaGen</A></B></H2></DIV></DIV><DIV class="row"><DIV class="col-sm-6" style="text-align:center;  border-right: 2px solid #efefef;"><H2 style="font-size:40px;"><B>Problem #1</B></H2><H4><B> Both antibiotic and phage treatment leads to endotoxin release</B></H4><H2 style="font-size:40px;"><B>Our solution</B></H2><BUTTON type="button" class="btn btn-outline-dark"><A href="https://2018.igem.org/Team:IISc-Bangalore/PAIR" target="_blank"><H4 style="font-size:40px;"><B>PAIR</B></H4></A></BUTTON><H5><B>Phage Assisted Immune Recruitment</B></H5></DIV><DIV class="col-sm-6" style="text-align:center; "><H2 style="font-size:40px;"><B>Problem #2</B></H2><H4><B>It is not easy to characterise the dosage of phage as opposed to antibiotics</B></H4><H2 style="font-size:40px;"><B>Our solution</B></H2><BUTTON type="button" class="btn btn-outline-dark"><A href="https://2018.igem.org/Team:IISc-Bangalore/Model" target="_blank"><H4 style="font-size:40px;"><B>Model</B></H4></A></BUTTON><H5><B>An attempt at finding dosage for a complex drug target interaction</B></H5></DIV></DIV><DIV><H2><B>References</B></H2><P style="font-size:11px !important;">[1]https://www.thebureauinvestigates.com/stories/2018-01-30/a-game-of-chicken-how-indian-poultry-farming-is-creating-global-superbugs
[2]World Health Organization. &quot;Critically important antimicrobials for human medicine: ranking of antimicrobial agents for risk management of antimicrobial resistance due to non-human use.&quot; (2017).</P></DIV></DIV><FOOTER id="footer"><DIV class="footer-text-boxes"><DIV class="footer-text-boxes-section"><DIV class="footer-text-boxes-section-heading">Links</DIV><UL><LI><A href="http://www.iisc.ac.in" target="_blank">IISc Bangalore</A></LI><LI><A href="https://iisc.ac.in/ug/" target="_blank">IISc UG Program </A></LI><LI><A href="https://2018.igem.org/Team:IISc-Bangalore/References">Complete list of references</A></LI></UL></DIV><A href="https://goo.gl/maps/BPKKwKU3hd32" target="_blank"><DIV class="footer-text-boxes-section"><DIV class="footer-text-boxes-section-heading">Address</DIV><UL><LI>Undergraduate department,</LI><LI>Indian Institute of Science,</LI><LI>Bangalore - 560012</LI></UL></DIV></A><DIV class="footer-text-boxes-section"><DIV><DIV class="footer-text-boxes-section-heading">Contact</DIV><UL><LI>Bhaskar Kumawat</LI><LI>Team Lead</LI><LI><A href="mailto:kbhaskar@iisc.ac.in" target="_blank">kbhaskar@iisc.ac.in</A></LI></UL></DIV></DIV></DIV><DIV class="footer-text-small" style="max-width:700px;">This website is best viewed on a 16:9 aspect ratio screen on the latest version of Google Chrome</DIV></FOOTER></DIV></DIV></DIV></DIV></DIV></BODY></HTML>